Hydrogen Utopia (HUI), a company specialising in turning non-recyclable mixed waste plastic into hydrogen has moved up from Aquis to the LSE this week without garnering any mainstream media press
Hydrogen Utopia (HUI), a company specialising in turning non-recyclable mixed waste plastic into hydrogen has moved up from Aquis to the LSE this week without garnering any mainstream media press
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is FTSE 100, Dax, Dow, Bitcoin, Avacta,
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s charts are FTSE 100, Dax, Dow, Bitcoin, Cable, Baron, Byotrol,
Harland & Wolff Group (HARL), the infrastructure projects group, released further details following yesterday’s announcement by the Secretary of State, The Rt Hon Ben Wallace MP, at the Appledore Shipyard
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is FTSE 100, Dax, Dow, Bitcoin, Alkemy,
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is FTSE 100, Dax, Dow, Bitcoin, Asiamet,
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is FTSE 100, Dax, Dow, Bitcoin, Argo,
It will be interesting to see whether after an incredible week Baron Oil (BOIL) can build further in share price terms.
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is FTSE 100, Bitcoin, Actual, Arc, Conroy,
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is FTSE 100, Bitcoin, Applied, Chill, Cellular,
Poolbeg Pharma (POLB), a clinical-stage infectious disease pharmaceutical company, said it has received ethics and competent authority approval to commence its Lipopolysaccharide human challenge clinical trial for POLB 001, which